Immunome Inc. (NASDAQ:IMNM) reported an insider purchase this week when President and CEO Clay B. Siegall acquired 25,450 shares of common stock on March 27, 2026, as disclosed in a Form 4 filing with the Securities and Exchange Commission.
The filing records a weighted average purchase price of $19.67 per share, with the transaction prices ranging from $19.63 to $19.70. The aggregate cost of the purchase was $500,601.
After the purchase was recorded, Siegall's direct holdings in Immunome total 690,704 shares.
Valuation context and market action
The purchase arrives alongside significant stock movement for Immunome. Over the past year the shares have risen 187%, but the company remains characterized by high volatility; the stock carries a beta of 2.2. Independent analysis from InvestingPro indicates the stock appears slightly overvalued relative to its Fair Value, while observers remain generally optimistic with published analyst price targets spanning $30 to $40.
Analyst coverage
H.C. Wainwright has recently initiated coverage of Immunome with a Buy rating and established a $40.00 price target. In its research note the firm highlighted Immunome's development of a portfolio of oncology assets addressing both solid tumor and hematologic indications.
H.C. Wainwright specifically called out Immunome's lead asset, varegacestat, describing it as a potentially superior gamma-secretase inhibitor for desmoid tumors when compared to the currently approved therapy Ogsiveo. The firm positioned this assessment as a reason for its favorable initial rating.
Investor resources mentioned
The InvestingPro platform is noted as providing additional perspective, including a set of 10 extra tips targeted at IMNM investors, according to the information cited alongside the valuation commentary.
Takeaway
The Form 4 filing documents a meaningful insider purchase by Immunome's CEO that coincides with renewed analyst attention and a sharp year-over-year price appreciation. The transaction and the analyst initiation provide data points investors may weigh alongside the firm's clinical and commercial outlook.